AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Court hearing scheduled for 9 September over acquisition dispute
- Cosette alleges breaches and seeks breakup fee or damages
- Shareholder vote on takeover set for 18 June
A high-stakes legal showdown is taking shape in the pharmaceutical sector as Mayne Pharma (ASX:MYX) and Cosette Pharmaceuticals prepare to face off in the NSW Supreme Court over the future of their proposed $672 million acquisition deal.
The legal dispute centers around the scheme implementation deed (SID) that was originally agreed upon in February this year. Mayne Pharma initiated court proceedings to push the SID forward after Cosette, a U.S.-based company, indicated its intention to terminate the agreement. The court date has now been officially set for 9 September.
Cosette has filed a cross-claim against Mayne, arguing that the SID may have already been terminated validly or could be considered void. The cross-claim also seeks compensation in the form of a breakup fee or, alternatively, unspecified damages. According to a statement released by Mayne, Cosette has further alleged that the company engaged in misleading or deceptive conduct, violating Australian Consumer Law.
While the dispute escalates legally, Mayne has maintained its stance, noting that Cosette’s cross-claim largely reiterates issues previously raised in two termination notices. The first of those notices cited a material adverse change in Mayne’s circumstances. The second pointed to alleged breaches in the representations and warranties made under the SID.
Despite the growing legal complexity, the acquisition is still technically in play. Mayne shareholders are scheduled to vote on the takeover proposal on 18 June. The outcome of that vote could significantly influence how the court ultimately rules in September.
The courtroom proceedings and shareholder decision are now critical flashpoints that will determine whether the acquisition proceeds or collapses under legal scrutiny. For stakeholders and investors alike, the coming weeks may offer pivotal clarity on the long-term direction of Mayne Pharma and its relationship with Cosette.
As the pharmaceutical landscape continues to evolve, this case underscores the legal and operational challenges that can arise even in meticulously structured corporate deals. The outcome could set important precedents for future transactions in the sector.
